Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.66 |
| ▸ | JAK2 | O60674 | 3/20 | 0.66 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.66 |
| ▸ | PRKACA | P17612 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.66 |
| ▸ | PRKCA | P17252 | 2/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 1/20 | 0.66 |
| ▸ | PRKCI | P41743 | 3/20 | 0.51 |
| ▸ | IKBKB | O14920 | 3/20 | 0.47 |
| ▸ | CHUK | O15111 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1718292 | 0.85 | JAK2 (0.72) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL10125013 | 0.84 | ROCK1 (0.67) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL12346400 | 0.83 | JAK2 (0.57) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL10124898 | 0.80 | JAK2 (1.00) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL12127503 | 0.76 | PRKCI (0.53) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL1718928 | 0.76 | PRKCI (0.53) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL12127819 | 0.75 | PRKCI (0.63) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL1717896 | 0.75 | PRKCI (0.58) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL1719640 | 0.73 | PRKCI (0.56) | ROCK1JAK2PRKCQPRKACAJAK3 | |
| SCHEMBL1718593 | 0.72 | PRKCI (0.63) | ROCK1JAK2PRKCQPRKACAJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| CN-101228161-B | Pyrrolopyridines useful as protein kinase inhibitors | VERTEX PHARMA | 2012-10-10 | — | — | CN | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| CN-101228161-A | Pyrrolopyridines useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2008-07-23 | — | — | CN | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | ROCK1 5/4885JAK2 1/4885PRKCQ 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.